'He then joined the Regional EU Commercial team in Pfizer Oncology. In 2012, Ben became UK Head of Pfizer Oncology where was heavily involved in shaping UK cancer policy through his work with government, PAGs and as a co-chair of the industry body’s cancer group. During his tenure he successfully led the organisation to gain access for patients to innovative cancer medicines through both NICE and the Cancer Drugs Fund. He also sat on the ‘NHS Molecular Diagnostics in Cancer working group’ and the South London Academic Health Science Network as the industry representative.'
Pfizer running the show?
Craig Murray had it wrong. He saw Astra Zeneca as the main beneficiary of the response to the virus with Cummings in the frame at the head.